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ABSTRACT
The clinical use of diethylstilbestrol (DES) by pregnant women has
resulted in an increased incidence of genital carcinoma in the daugh-
ters born from these pregnancies. Also, in the so-called DES-sons
abnormalities were found, mainly, the presence of Mu¨llerian duct
remnants, which indicates that fetal exposure to DES may have an
effect on male sex differentiation. Fetal regression of the Mu¨llerian
ducts is under testicular control through anti-Mu¨llerian hormone
(AMH). In male mice, treated in utero with DES, the Mu¨llerian ducts
do not regress completely, although DES-exposed testes do produce
AMH. We hypothesized that incomplete regression in DES-exposed
males is caused by a diminished sensitivity of the Mu¨llerian ducts to
AMH. Therefore, the effect of DES on temporal aspects of Mu¨llerian
duct regression and AMH type II receptor (AMHRII) messenger RNA
(mRNA) expression in male mouse fetuses was studied.
It was observed that Mu¨llerian duct regression was incomplete at
E19 (19 days post coitum), upon DES administration during preg-
nancy from E9 through E16. Furthermore, analysis of earlier time
points of fetal development revealed that the DES treatment had
clearly delayed the onset of Mu¨llerian duct formation by approxi-
mately 2 days; in untreated fetuses, Mu¨llerian duct formation was
complete by E13, whereas fully formed Mu¨llerian ducts were not
observed in DES-treated male fetuses until E15.
Using in situ hybridization, no change in the localization of AMH
and AMHRII mRNA expression was observed in DES-exposed male
fetuses. The mRNA expression was quantified using ribonuclease
protection assay, showing an increased expression level of AMH and
AMHRII mRNAs at E13 in DES-exposed male fetuses. Furthermore,
the mRNA expression levels of Hoxa 11 and steroidogenic factor-1
(SF-1) were determined as a marker for fetal development. Prenatal
DES exposure had no effect on Hoxa 11 mRNA expression, indicating
that DES did not exert an overall effect on the rate of fetal develop-
ment. In DES-exposed male fetuses, SF-1 showed a similar increase
in mRNA expression as AMH, in agreement with the observations
that the AMH gene promoter requires an intact SF-1 DNA binding
site for time- and cell-specific expression, although an effect of DES
on SF-1 expression in other tissues, such as the adrenal and pituitary
gland, cannot be excluded. However, the increased expression levels
of AMH and AMHRII mRNAs do not directly explain the decreased
sensitivity of the Mu¨llerian ducts to AMH. Therefore, it is concluded
that prenatal DES exposure of male mice delays the onset of Mu¨lle-
rian duct development, which may result in an asynchrony in the
timing of Mu¨llerian duct formation, with respect to the critical period
of Mu¨llerian duct regression, leading to persistence of Mu¨llerian duct
remnants in male mice. (Endocrinology 139: 4244–4251, 1998)
ANTI-MU¨LLERIAN hormone (AMH), a member of thetransforming growth factor b (TGFb) superfamily of
peptide growth and differentiation factors, is the earliest
protein known to be secreted by the fetal Sertoli cells (1, 2).
In contrast to other family members, which have a broad
range of functions, AMH has a very specific role during sex
differentiation. AMH, which is produced only by the fetal
testes and not by the ovaries during fetal development, might
play a role in gonadal differentiation, as indicated by the
formation of ovotestes in female mice overexpressing AMH
(3). Most importantly, in the male, AMH induces the regres-
sion of the Mu¨llerian ducts, which form the anlagen of the
uterus, oviducts, and upper part of the vagina. It has been
shown that the timing of AMH action on the Mu¨llerian ducts
is very critical. In the rat, exposure of female fetuses to AMH
after E16 (16 days post coitum) does not result in Mu¨llerian
duct regression (4, 5).
The cellular and molecular mechanisms by which AMH
induces Mu¨llerian duct regression are poorly understood.
However, the identification and cloning of the AMH type II
receptor (AMHRII) has contributed to the elucidation of this
question (6, 7). AMHRII messenger RNA (mRNA) is ex-
pressed in the fetal gonads and in the mesenchymal cells
located adjacent to the Mu¨llerian duct epithelium, which
corresponds to the sites of action of AMH (6, 7). Recent
results have shown that AMH elicits its effect on the Mu¨l-
lerian duct epithelium via the surrounding mesenchymal
cells, a process which may also involve induction of pro-
grammed cell death (4, 8).
AMHRII is a member of the transmembrane serine/thre-
onine kinase receptor family, to which also the TGFb and
activin receptors belong (9). Members of the TGFb super-
family exert their action through a heteromeric signaling
complex consisting of a type I and a type II receptor (10).
Failure in AMH action, as a result of a gene mutation leading
to either inactive AMH or AMHRII, causes inhibition of
Mu¨llerian duct regression, resulting in a rare form of
pseudohermaphroditism in man known as persistent Mu¨l-
lerian duct syndrome (11, 12). Gene knockout experiments
in mice have confirmed that, in the absence of AMH or
AMHRII, Mu¨llerian ducts do not regress (13, 14).
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In chickens, unilateral regression of Mu¨llerian ducts oc-
curs in the female. The left Mu¨llerian duct is retained,
whereas the right Mu¨llerian duct regresses, because of the
fact that, in contrast to mammalian species, AMH is also
expressed by the fetal ovary (15). It has been suggested that
estrogens protect the left duct from regression. This is sup-
ported by the observation that the concentration of estrogen
receptor in the left duct is higher than that in the right duct
(16). Furthermore, inhibition of estrogen production in fe-
male chick fetuses, by treatment with an aromatase inhibitor
during egg incubation, resulted in regression of both ducts
(17). Exposure to estrogen during egg incubation prevents
Mu¨llerian duct regression in both male and female chick
fetuses (18, 19).
Although it is a large step from chicken to human, it is of
interest to compare the data from the experiments with chick-
ens with clinical data. In humans, intrauterine exposure to
diethylstilbestrol (DES), a potent synthetic estrogen that has
been administrated during pregnancy to prevent miscar-
riages, has led to an increased incidence of reproductive tract
abnormalities. The effects of prenatal DES exposure in so-
called DES-daughters, such as an increased risk of genital
carcinoma, have been well documented (20). However, also
the sons born from DES-controlled pregnancies have an in-
creased incidence of genital tract abnormalities, including
epididymal cysts, cryptorchidism, and the presence of Mu¨l-
lerian duct remnants (21, 22). This indicates that DES has an
effect on male sex differentiation. To study the prenatal ef-
fects of DES on the developing genital tract in an animal
model, McLachlan et al. (23) injected DES daily into pregnant
mice during the phase of growth and differentiation of the
fetal reproductive tract. Observations on the male offspring
of these DES-treated mice indicated that the developing re-
productive tract of the fetus is sensitive to DES exposure.
Hypoplastic testes and Mu¨llerian duct remnants were found
(23, 24). It is, however, not clear how DES mediates its in-
hibitory effect on reproductive tract differentiation.
In a mouse organ culture system, after in vivo DES treat-
ment, Newbold et al. (25) studied whether the inhibitory
effect of DES on Mu¨llerian duct regression results from sup-
pression of fetal testicular AMH production or a change in
responsiveness of the Mu¨llerian ducts to AMH. Control Mu¨l-
lerian ducts regressed normally when cultured in the pres-
ence of control testes, whereas DES-exposed Mu¨llerian ducts
in the presence of DES-exposed testes did not regress. Com-
bination of control Mu¨llerian ducts and DES-exposed testes
resulted in normal regression. However, in the reciprocal
combination, DES-exposed ducts and control testes, only
partial regression of the Mu¨llerian ducts was observed. These
results indicate that DES-exposed testes still produce bioac-
tive AMH and that the effect of DES is caused mainly by a
decrease in AMH responsiveness of the Mu¨llerian ducts.
We hypothesized that the change in sensitivity of the Mu¨l-
lerian ducts to AMH may result from an effect of DES on the
expression of AMHRII. In this paper, we describe the effects
of DES exposure of mouse male fetuses on the Mu¨llerian
ducts; in particular, AMH and AMHRII mRNA expression
during the period of reproductive tract differentiation. As a
control for possible effects of DES exposure on general fetal
development (26, 27), the expression of Hoxa 11 mRNA was
measured. The mRNA expression level for steroidogenic
factor-1 (SF-1) mRNA, an orphan nuclear receptor essential
for the development of steroidogenic tissues (28), was mea-
sured as a control for possible effects of DES exposure on
urogenital ridge development. The results of this study may
contribute to our knowledge about the possible involvement
of exposure to exogenous estrogenic compounds in the pos-
tulated increased incidence of reproductive tract disorders in
wild-life and perhaps also in humans (29, 30).
Materials and Methods
Animals and treatment
FVB mice were kept under standard animal housing conditions in
accordance with NIH Guidelines for the Care and Use of Experimental
Animals. Vaginal plug detection was considered day 0 (E0) of preg-
nancy. Pregnant mice were given daily sc injections with DES (100
mg/kg BW; Janssen Chimica, Beerse, Belgium) dissolved in olive oil, or
olive oil alone, on days E9–E16 of gestation. Pregnant mice were killed
by cervical dislocation at E13, E14, E15, E17, or E19 of gestation. Fetuses
were isolated and snap-frozen in liquid nitrogen and stored at 280 C.
Total RNA was isolated using the LiCl/urea method (31). In addition,
fetuses from the same litter were also fixed overnight in 4% parafor-
maldehyde, embedded in paraffin, and sectioned transversally at 7 mm.
PCR reactions, using placental genomic DNA (32), were performed as
described by Mitchell et al. (33) using primers for the mouse genes Sbx
and Sby (34) to determine the sex of the fetuses.
In situ hybridization
A PstI fragment containing bp 1243–1640 of the rat AMHRII com-
plementary DNA (cDNA) and an NheI fragment containing bp 38–400
of the rat AMH cDNA were subcloned in pBluescript KS (Stratagene,
Westburg, Leusden, The Netherlands) and used to generate sense and
antisense [35S]-uridine 59-triphosphate (UTP)-labeled (Amersham, ‘s
Hertogenbosch, The Netherlands) transcripts in vitro. In situ hybridiza-
tion was performed as described by Zeller and Rogers (35), with some
modifications (6). Sections were mounted on slides that were coated with
3-aminopropyl-ethoxysaline. After deparaffinization, sections were
treated with 0.2 m HCl (20 min), treated with proteinase K (1 mg/ml in
0.2 m Tris (pH 7.5), 2 mm CaCl2; incubation for 15 min at 37 C), and
postfixed in 4% paraformaldehyde in 0.1 m PBS. After treatment with
dithiothreitol and blocking of nonspecific binding with 0.1 m trietha-
nolamine, followed by 0.1 m triethanolamine and acetic anhydride,
sections were incubated with [35S]-UTP-labeled antisense and sense
AMH and AMHRII RNA probes at a final concentration of 5 3 105
cpm/ml. Hybridization was carried out as described previously (6).
Sections were exposed at 4 C for 1 week, developed, counterstained with
hematoxylin, and mounted.
Ribonuclease (RNase) protection assay
A mouse AMHRII DNA template for in vitro transcription was gen-
erated by RT-PCR. The RT-PCR reaction was carried out on 100–200 ng
total RNA, extracted from 25-day-old mouse testis, using random hex-
amers. A sample of the RT reaction product was used in the PCR reaction
using the primers 59GCTCCGGAGCTCTTGGACAAG39 (forward
primer) and 59CAGGCGCTGCTGCACACACTC39 (reverse primer) cor-
responding to kinase subdomains VIII, IX, and X of the AMHRII gene
transcript. A 350-bp PCR product was subcloned in pBluescript KS and
used to generate [32P]-UTP-labeled antisense probe. The AMH RNA
probe was obtained using a 430-bp PstI fragment, containing exon 1, of
mouse genomic DNA. The SF-1 RNA probe was obtained using a 252-bp
HindIII-EcoRI fragment of mouse SF-1 cDNA (36). The Hoxa 11 RNA
probe was obtained using a 300-bp BamHI-BglII fragment of the mouse
Hoxa 11 cDNA (26). The control glyceraldehyde 3-phosphate dehydro-
genase (GAPD) RNA probe was synthesized using a construct contain-
ing a 163-bp AccI-Sau3AI fragment of the rat GAPD cDNA. RNase
protection assays of 50 mg total fetal RNA with these probes were
performed as described by Baarends et al. (6). GAPD was used as a
control for RNA loading. The relative amount of protected mRNA band
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was quantified through exposure of the gels to a phosphor screen (Mo-
lecular Dynamics, B and L Systems, Zoetermeer, The Netherlands),
followed by a calculation of the relative density of the obtained bands
using a phospho-imager and Image Quant (Molecular Dynamics) as
computer analysis software. The arbitrary units are expressed as the
rations after division by the corresponding GAPD values.
Results
Effect of DES exposure on Mu¨llerian duct formation
The development of the Mu¨llerian duct was studied in
male fetuses at E13, E15, and E19, at three positions along the
axis of the Mu¨llerian ducts (Figs. 1, 2, and 3). Position I
indicates the most cranial part of the ducts, at the level of the
fetal testes. Position II is at the level where the Mu¨llerian and
Wolffian ducts cross each other. Position III indicates the
caudal part of the Mu¨llerian ducts, near the urogenital sinus.
In control fetuses at E13, no morphological signs of re-
gression could be detected along the axis of the Mu¨llerian
ducts (Fig. 1, A–D). In DES-exposed E13 fetuses, on the other
hand, Mu¨llerian ducts were only found at position I (Fig. 1F).
Caudally, at positions II and III, the Mu¨llerian ducts were not
formed, indicating a delay in their formation caused by the
DES treatment (Fig. 1I, position III).
At E15, differences in Mu¨llerian duct regression between
control and DES-exposed fetuses were observed. In E15 con-
trol fetuses, regression of the Mu¨llerian ducts had started but
was not complete (Fig. 2, A–D). The regression of the Mu¨l-
lerian ducts was initiated cranially at position I, and con-
comitantly, we observed the characteristic presence of a
whorl of mesenchymal cells surrounding the Mu¨llerian ducts
(Fig. 2A). No signs of Mu¨llerian duct regression could be
detected at positions II and III at E15, indicating that degen-
eration of the Mu¨llerian ducts is initiated cranially and then
progresses caudally (Fig. 2D). In contrast, regression of the
Mu¨llerian ducts in the DES-exposed E15 fetuses was not
initiated at all three positions, as indicated by the absence of
the typical whorl of mesenchymal cells (Fig. 2, F–I). The
appearance of the Mu¨llerian ducts in DES-exposed fetuses at
E15 corresponds to that of the Mu¨llerian ducts in control
fetuses at E13, implicating that the onset of Mu¨llerian duct
regression is delayed by approximately 2 days.
It was observed that regression of the Mu¨llerian ducts in
control male fetuses resulted in their complete absence at E19
(Fig. 3A). In the DES-exposed male fetuses at E19, regression
of the cranial part of the Mu¨llerian ducts was complete at
positions I and II, because no Mu¨llerian structures could be
detected (results not shown). However, more caudally, at
position III, the Mu¨llerian ducts were still present (Fig. 3B).
The epithelial and mesenchymal cells of the Mu¨llerian duct
remnants, in DES-exposed male fetuses at E19 (Fig. 3B), were
differentiated and had an appearance comparable with that
found in control female fetuses of the same developmental
stage (results not shown).
These results are schematically summarized in the top
panels of Figs. 1, 2, and 3.
Expression of AMH and AMHRII mRNAs
The expression of AMH and AMHRII mRNAs was studied
by in situ hybridization. AMH mRNA expression was local-
ized in the gonads of DES-exposed male fetuses, similar to
FIG. 1. Histology of Mu¨llerian ducts and expression of AMH and
AMHRII mRNAs in control and DES-exposed male mouse fetuses at
E13. The formation of the Mu¨llerian ducts is represented schemati-
cally in the top panel. The Roman numerals indicate positions I, II,
and III, at which sections were taken for morphology study and in situ
hybridization. The left figures (position I: A, B, C; position II: D, E) and
the right figures (position I: F, G, H; position II: I, J) are sections from
control and DES-exposed fetuses, respectively. At position I, the Mu¨l-
lerian ducts are present in control fetuses (A) and in DES-exposed
fetuses (F), although less differentiated. At position II, the Mu¨llerian
ducts are found in control (D) but not in DES-exposed fetuses (I).
Expression of AMH and AMHRII mRNAs was determined using in
situ hybridization. Darkfield views of AMHRII (control: B, E; DES-
exposed: G, J) and AMH (control: C; DES-exposed: G) mRNAs are
shown in adjacent sections. No difference between control and DES-
exposed fetuses is found in the localization of AMH and AMHRII
mRNAs expression; AMH mRNA expression is found in the testes,
and AMHRII mRNA expression is found in the testes and the mes-
enchymal cells surrounding the Mu¨llerian ducts. Arrows, Expression
sites; T, testis; W, Wolffian duct; M, Mu¨llerian duct. The scale bar
represents 100 mm.
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control fetuses, although differences in the quantitative level
of expression were detected. The testes of DES-exposed fe-
tuses at E13 showed a marked increase in AMH mRNA
expression, compared with control testes (Fig. 1, C–H). This
increase in AMH mRNA expression was also present on E15
(Fig. 2, C–H), whereas testicular expression of AMH mRNA
could hardly be detected in both control and DES-exposed
E19 fetuses (results not shown).
AMHRII mRNA expression was also studied at the three
positions indicated in Fig. 1. Expression of AMHRII mRNA
in DES-exposed fetuses was found in the same tissues as in
control fetuses, the fetal gonads and the mesenchymal cells
surrounding the Mu¨llerian ducts (Fig. 1, B–G). It is important
to note that, although the formation of the Mu¨llerian ducts
was not complete by E13 in DES-exposed fetuses, AMHRII
mRNA was already expressed. More caudally, at positions II
and III, the Mu¨llerian ducts were absent in DES-exposed
fetuses; hence, expression of AMHRII mRNA could not be
detected at these sites (Fig. 1J). In control fetuses, AMHRII
mRNA was expressed along the whole axis of the Mu¨llerian
ducts, although expression decreased caudally (Fig. 1B/E).
In control fetuses at E15, expression of AMHRII mRNA
could no longer be detected in the mesenchymal cells sur-
rounding the Mu¨llerian ducts, at all three positions studied
(Fig. 2B/E). The mesenchymal cells of the cranial Mu¨llerian
ducts in DES-exposed E15 fetuses did still express AMHRII
mRNA (Fig. 2G), although the expression was lower, com-
pared with that in E13 DES-exposed fetuses. Caudally, at
position III, expression could not be detected (Fig. 2J). In the
testes of control fetuses, AMHRII mRNA was only weakly
expressed, whereas the testes of DES-exposed fetuses at E15
still showed a clear AMHRII mRNA expression (Fig. 2B/G).
An increase in testicular AMH mRNA expression in DES-
exposed fetuses, compared with control fetuses, was still
observed at E15 (Fig. 2C/H).
At E19, testicular AMHRII mRNA expression was equally
low in both control and DES-exposed fetuses. AMHRII
mRNA expression in the mesenchymal cells of the Mu¨llerian
ducts could not be detected in control and DES-exposed
fetuses, although the Mu¨llerian ducts were still present in
FIG. 3. Histology of Mu¨llerian ducts in control and DES-exposed
male mouse fetuses at E19. In the top panel, the regression of the
Mu¨llerian ducts is represented schematically. At position III, the
Mu¨llerian ducts have completely regressed in control fetuses (A),
whereas in DES-exposed fetuses, remnants of Mu¨llerian ducts are
clearly visible (B). The Mu¨llerian duct remnants show differentiation
of epithelial and mesenchymal cells. W, Wolffian duct; M, Mu¨llerian
duct. The scale bar represents 100 mm.
FIG. 2. Histology of Mu¨llerian ducts and expression of AMH and
AMHRII mRNAs in control and DES-exposed male mouse fetuses at
E15. In the top panel, the regression of the Mu¨llerian ducts is rep-
resented schematically. The stippled lines indicate the regressed Mu¨l-
lerian ducts. The left figures (position I: A, B, C; position III: D, E) and
the right figures (position I: F, G, H; position III: I, J) are sections from
control and DES-exposed fetuses, respectively. Regression has initi-
ated in control fetuses at position I (A), but not at positions II and III
(D). In DES-exposed fetuses, the Mu¨llerian ducts are completely
present (F, I), although no signs of regression are found at position I
(F). Note the presence of a whorl of mesenchymal cells surrounding
the Mu¨llerian duct in control fetuses (A). Expression of AMH and
AMHRII mRNAs was determined using in situ hybridization. Dark-
field views of AMHRII (control: B, E; DES-exposed: G, J) and AMH
(control: C; DES-exposed: H) mRNAs are shown in adjacent sections.
AMH and AMHRII mRNA expression is increased in fetal testes of
DES fetuses. At position I, mesenchymal cells of control fetuses do not
express AMHRII mRNA, whereas in DES-exposed fetuses, a low
expression is found. At position III, no expression of AMHRII was
found. Arrows, Expression sites; T, testis; W, Wolffian duct; M, Mu¨l-
lerian duct. The scale bar represents 100 mm.
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DES-exposed male fetuses near the urogenital sinus (results
not shown).
Expression levels of AMH and AMHRII mRNAs were
quantified more precisely using an RNase protection assay
(Fig. 4A). Furthermore, the expression of SF-1 mRNA was
included as a marker for urogenital ridge development. The
results of the RNase protection showed that the expression
patterns of AMH and AMHRII mRNAs mimic the expression
pattern of SF-1 mRNA (Fig. 4B). In DES-exposed male fetuses
at E13 the expression of SF-1 mRNA is strongly increased,
compared with control fetuses. A similar increase in AMH
mRNA expression was measured in DES-exposed male fe-
tuses, as was observed with in situ hybridization. An increase
of AMHRII mRNA expression was found, using RNase pro-
tection assay in DES-exposed fetuses at E13, although this
increase was less evident, compared with AMH and SF-1
mRNAs expression. At E14 and E15, DES-exposed fetuses
showed a higher expression of SF-1, AMH, and AMHRII
mRNAs than control fetuses, although less pronounced than
at E13. From E15 onwards, changes in mRNA expression of
SF-1, AMH, and AMHRII were limited to a slight increase at
E19.
In addition to the expression of SF-1 mRNA, the Hoxa 11
mRNA expression level was determined, as a control for a
possible effect of DES treatment on the general rate of fetal
development. It was observed that DES-treated fetuses were
born 1 day later, compared with control fetuses. This might
indicate that the DES-induced delay in Mu¨llerian duct for-
mation would reflect a general delay in fetal development of
DES fetuses. However, DES-treated and control fetuses did
not show a difference in fetal Hoxa 11 mRNA expression at
all time points studied (Fig. 4), indicating similar rates of
general fetal development in the two treatment groups. Fur-
thermore, no differences in length, width, or digit differen-
tiation were observed between control and DES-treated fe-
tuses during fetal development (results not shown).
Discussion
This paper describes the effect of prenatal DES exposure
on regression of the Mu¨llerian ducts of fetal male mice. In
agreement with previous studies (23, 24), we found incom-
plete Mu¨llerian duct regression upon DES exposure. In male
fetuses from DES-treated mice, regression had initiated in the
cranial part of the Mu¨llerian ducts but did not progress
completely caudally, leaving remnants of Mu¨llerian ducts at
the position of the urogenital sinus. The nonregressed parts
of the Mu¨llerian ducts showed female-like differentiation,
indicating that the Mu¨llerian duct remnants might be re-
sponsive to estrogens. In female mice, prenatal exposure to
DES also causes uterine epithelial cell hypertrophy (37).
These findings indicate that the Mu¨llerian ducts are a target
for DES action in both male and female fetuses.
In addition to the appearance of Mu¨llerian duct remnants,
we observed that DES exposure resulted in a delay in Mu¨l-
lerian duct formation of approximately 2 days. In control
fetuses, the complete Mu¨llerian ducts were present at E13,
whereas in DES-exposed fetuses fully formed Mu¨llerian
ducts were not found before E15. In addition, DES-exposed
fetuses were born 1 day later, compared with control fetuses.
These observations suggest that DES causes a delay in gen-
eral embryonic development. Also, in rats, exposure to es-
trogens during pregnancy leads to a prolonged gestation
(38), but this is explained by an inhibiting effect of DES on
the onset of uterine contraction. Cesarean sections, per-
formed to rescue the litter, revealed no difference in size of
fetuses from control and DES-treated mothers (38). Trans-
genic mice, overexpressing the estrogen receptor a (ERa),
have similar problems with birth, with gestation lengths
prolonged up to 4 days (39). Exposure to DES in neonatal
mice results in an increase of ERa mRNA expression in
uterine cells (40), suggesting that the longer gestation time in
FIG. 4. Quantitative analysis of the expression of AMH, AMHRII,
SF-1, and Hoxa 11 mRNAs in control and DES-exposed fetuses, stud-
ied by RNase protection assay. Expression in whole fetuses was de-
termined at E13, E14, E15, E17, and E19. A, Results of the RNase
protection assay; B, quantitative analysis of the expression levels. The
mRNA expression levels are expressed as the ratios: AMH/GAPD,
AMHRII/GAPD, SF1/GAPD, and Hoxa 11/GAPD. Open bars, Control
fetuses; filled bars, DES-exposed fetuses. The bars and error bars
represent the mean and SD of two fetuses, isolated from different
treatments.
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DES-exposed mice may be a phenocopy of the change in
pregnancy in ERa transgenic mice, and this reflects a ma-
ternal effect rather than a delay in fetal development. No
differences in body size or digit differentiation were ob-
served between control and DES-treated fetuses during fetal
development (results not shown). Furthermore, the expres-
sion of Hoxa 11 mRNA was studied as a marker for general
fetal development (26, 27). Hoxa 11 mRNA is expressed in
the limbs, in the kidneys, and in the stromal cells surround-
ing the Mu¨llerian and Wolffian ducts, and this expression is
detected at E10 several days before reproductive tract dif-
ferentiation (26). In the present study, no difference in Hoxa
11 mRNA expression between control and DES-exposed fe-
tuses was observed, at all embryonic stages studied. This
indicates that the rate of general fetal development is not
affected but that DES elicits a specific effect on reproductive
tract development. The variation in the results with the Hoxa
11 probe is caused by the large differences in specific activity
of the probe in different experiments.
The anlagen of the reproductive tract, the Wolffian and
Mu¨llerian ducts, are formed separately. The Wolffian duct is
formed as an excretory duct of the mesonephros and is rec-
ognizable before the gonads are formed. At the time of gonad
formation, the Mu¨llerian ducts develop in a cranial-to-caudal
direction along the Wolffian ducts, which function as a guid-
ing structure for early growth of the Mu¨llerian ducts (Ref. 41,
and references therein). The genes involved in Mu¨llerian
duct formation have not been identified yet. It has been
suggested that the Wolffian ducts release epithelial cells,
which contribute to the developing Mu¨llerian ducts (42). It
has also been suggested that the growth of Mu¨llerian ducts
is autonomous (43). In our studies, DES treatment affects the
formation of the Mu¨llerian ducts rather than formation of the
Wolffian ducts, because DES was administered after com-
pletion of Wolffian duct formation. However, an effect of
estrogens on Wolffian duct formation cannot be ruled out. It
has been observed that the Wolffian ducts are affected by
exogenous estrogen exposure, resulting in several abnormal-
ities, such as seminal vesicle tumors and prostate inflamma-
tion (44). Also in female fetuses, the Wolffian ducts are a
target for DES action. Retention of Wolffian ducts, postna-
tally, was observed in females, both in humans and in mice
(45, 46). These effects of DES on Wolffian and Mu¨llerian duct
differentiation may point to a common mechanism in the
development of these duct systems. Both Wolffian and Mu¨l-
lerian ducts can respond to estrogens, because the ERa is
present in both structures during development (47). The
identification of a novel estrogen receptor, ERb (48), may
contribute to our understanding of the mechanism of DES
action. Recently, it was reported that ERa and ERb, when
activated by estradiol, signal in opposite ways from an AP1
site (49). DES, therefore, may cause different effects, depend-
ing on the tissue studied. ERb is highly expressed in prostate
and ovary, whereas ERa shows a higher expression in the
uterus (50). Studying the effects of prenatal DES exposure in
ERa, ERb, or double-knockout mice, will reveal which ER
type is mainly involved in DES action.
In previous studies, it has been proposed that incomplete
regression of the Mu¨llerian ducts in fetuses exposed to ex-
ogenous estrogens is a result of a change in sensitivity of the
ducts to AMH (25). Therefore, we have studied the effect of
DES on AMHRII mRNA expression. The expression of AMH
and AMHRII mRNAs was studied by in situ hybridization,
and the expression levels in total fetuses were quantified by
RNase protection. With in situ hybridization, a strong in-
crease in AMH mRNA expression in the fetal testes of DES-
exposed fetuses was evident. Quantification of the expres-
sion revealed a 2-fold increase of AMH mRNA expression in
DES-exposed fetuses, compared with controls. This increase
was most significant at E13. Nevertheless, this higher AMH
mRNA expression did not result in complete Mu¨llerian duct
regression. This is in agreement with the observations in in
vitro studies that addition of a relatively high dose of AMH
did not result in full regression of Mu¨llerian ducts from
DES-exposed fetuses (Newbold et al., personal communica-
tion). The DES-induced increase in AMH mRNA expression
implies a direct effect of estrogens on the regulation of AMH
mRNA expression. Indeed, a 13-bp palindromic sequence,
nearly identical to the estrogen response element (ERE), has
been identified in the AMH gene promoter (51). In footprint-
ing experiments, this site was shown to bind ERa. Further-
more, 39 ERE half-sites were identified in the 59 flanking
sequences of the AMH gene (52). Clusters of half-sites or
degenerate palindromic sites can be effective, as was shown
in vitro, where several ERE half-sites can act synergistically
to control expression of the ovalbumin gene (53). However,
the functionality of the ERE half-sites in the AMH gene has
not been proven. Recent papers have shown that AMH ex-
pression is dependent on SF-1 (54, 55). SF-1, an orphan nu-
clear receptor expressed in adrenals, gonads, and the gona-
dotrophes of the pituitary gland, was characterized as a
transcription factor that regulates several genes, such as
genes encoding steroidogenic enzymes (36). SF-1 knockout
mice lack gonads and adrenals, revealing an essential role for
SF-1 in sexual differentiation and formation of primary ste-
roidogenic tissues (28). In in vivo experiments, it was dem-
onstrated that the proximal AMH gene promoter requires an
intact binding site for SF-1 for time- and cell-specific expres-
sion (55). We observed a strong increase in SF-1 mRNA
expression in DES-exposed fetuses, which was most signif-
icant at E13 and decreased toward E17. The increased ex-
pression of AMH mRNA in DES-exposed mice was found to
have a similar temporal pattern as the SF-1 mRNA expres-
sion, corresponding with the role of SF-1 in regulation of
AMH gene expression. These data suggest that DES has an
effect on fetal gonadal gene expression. An effect of prenatal
exposure to estrogenic compounds on SF-1 mRNA expres-
sion has been reported previously, although the described
effect is a down-regulation of SF-1 mRNA expression (56). In
that study by Majdic et al. (56), DES or the estrogenic com-
pound 4-octylphenol were injected twice during pregnancy
(E11 and E15), and expression of SF-1 mRNA was measured
in the fetal testis at E17 (56). The disagreement between their
and our results may be explained by the animal model, the
experimental procedure, and the time points at which ex-
pression was determined.
In the present study, expression of AMHRII mRNA was
also found to be increased at E13 in DES fetuses, although this
increase was less obvious and could not be detected by in situ
hybridization. In in vitro studies, no direct regulation of the
DES EFFECT ON MU¨LLERIAN DUCT DEVELOPMENT 4249
 at Medical Library Erasmus MC on December 11, 2006 endo.endojournals.orgDownloaded from 
AMHRII promoter by estrogens was found (Visser et al.,
unpublished results). Therefore, it is likely that DES influ-
ences AMHRII mRNA expression indirectly. In the DNA
sequence of both the human and mouse AMHRII gene pro-
moter, a SF-1 response element was identified (Ref. 12, and
results not shown). Although regulation of AMHRII mRNA
expression by SF-1 has not been reported, the increased
AMHRII mRNA expression in DES-exposed fetuses might be
a consequence of an increased SF-1 level. In accordance with
developmental changes in SF-1 and AMH mRNA expres-
sion, the most pronounced increase in AMHRII mRNA ex-
pression was found at E13, and this increase becomes less
evident in older fetuses.
The increased mRNA expression levels of AMH and
AMHRII do not directly explain the decreased sensitivity of
the Mu¨llerian ducts to AMH. However, a DES-induced effect
on factors downstream of AMHRII, such as a type I receptor
or Smad proteins, cannot be excluded. One can hypothesize
that a DES-induced inhibition of downstream signaling fac-
tors influences a negative feedback loop, resulting in an
increased expression of AMH and AMHRII mRNA, although
the existence of such a feedback system for AMH has not
been reported yet. Furthermore, whether the increase mRNA
expression levels result in higher protein levels remains to be
studied.
The in situ hybridization demonstrated that AMHRII
mRNA expression can be detected along the entire axis of the
Mu¨llerian ducts in control fetuses at E13, but it decreases in
caudal direction toward the urogenital sinus. At E15, ex-
pression of AMHRII mRNA could not be detected in the
regressed cranial part of the Mu¨llerian ducts. However, also
in the caudal part of the Mu¨llerian ducts, AMHRII mRNA
expression could hardly be detected. These observations sug-
gest that the onset of the critical period for AMH sensitivity
of the Mu¨llerian ducts (E13) is at the time point when Mu¨l-
lerian ducts are completed and express the AMHRII,
whereas the end of this critical period (E15) is demarcated by
disappearance of the receptor. In DES-exposed fetuses at E13,
AMHRII mRNA expression was found in the cranial part of
the Mu¨llerian ducts. The caudal parts have not been formed,
and expression could not be detected at this site, suggesting
that AMHRII mRNA expression is dependent on the pres-
ence of a formed Mu¨llerian duct. At E15, a time point at
which the Mu¨llerian ducts have completely formed in the
DES-exposed fetuses, AMHRII mRNA expression was de-
tectable in the cranial ducts, although expression was much
lower, compared with E13. Caudally, expression could
hardly be detected, comparable with expression in control
E15 fetuses. In DES-exposed mice just before birth (E19), the
Mu¨llerian duct remnants had lost expression of AMHRII
mRNA and, therefore, are unable to respond to AMH at this
late developmental time point. Although the formation of the
Mu¨llerian ducts is delayed in DES-treated fetuses, the timing
of AMHRII mRNA expression is not delayed. This probably
leads to a temporal asynchrony between the presence of the
Mu¨llerian ducts and the onset of the critical period of Mu¨l-
lerian duct regression.
The present observation on the DES-induced delay in Mu¨l-
lerian duct formation contributes to our understanding of the
diversity of developmental defects in affected DES-sons. In
humans, exposure of mothers to DES during early pregnancy
results in a 2-fold increase in the prevalence of malformations
in their sons (57). The formation of the Mu¨llerian ducts is
completed before the 11th week of gestation, and Mu¨llerian
duct regression is initiated at the 11th week. Exposure to DES
after this period results in less abnormalities, whereas ex-
posure before the 11th week results in a higher incidence of
Mu¨llerian duct remnants in the DES-sons (57). This is in
concordance with the present observations in mice, and we
suggest that, also in humans, administration of DES during
early pregnancy causes an asynchrony between Mu¨llerian
duct formation and the critical period of Mu¨llerian duct
regression.
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